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Abstract. The aim of the present study was to determine 
whether BCL6 is expressed during malignant transforma-
tion of the large bowel and to assess whether, and to what 
extent, immunoreactivity is related to the different stages of 
neoplastic progression. Samples of normal colorectal mucosa 
(n=22), microadenomas (n=22) and colorectal cancer (n=22), 
were analyzed by immunohistochemistry, immunofluores-
cence coupled with confocal microscopy and western blotting. 
Our results clearly outlined the marked increase occurring 
in both intensity and density of BCL6 protein expression in 
the normal mucosa-microadenoma-carcinoma sequence. 
Immunohistochemistry and immunofluorescence analyses 
showed that BCL6 is expressed at low levels in normal mucosa 
and increases in microadenoma and in cancer with statistical 
significance. These results were confirmed by western blotting 
data. The increasing expression of BCL6 in human colorectal 
cancer development suggests the involvement of BCL6 in tumor 
progression, from the earliest stages of carcinogenesis with 
significant increase in cancer. The enhanced understanding 
of the biological role of BCL6, previously shown to exert a 
key role in lymphomagenesis, may lead to a re-evaluation of 
this protein and may highlight the importance of performing 
further studies in order to identify novel therapeutic targets for 
colorectal cancer.
Introduction
BCL6 is a transcriptional repressor which has emerged as a 
critical regulator of germinal centers (GCs) of lymph nodes. 
BCL6 is also a frequently activated oncogene in the patho-
genesis of human B cell lymphomas, most of which derive 
from the GC B cells (1). Especially in the last 10 years, knowl-
edge concerning this gene and its expression has improved 
considerably. Identification of factors acting together with the 
BCL6 protein as well as delineation of several target genes 
have allowed a determination of its biological function. This 
set of BCL6 targets points to a number of cellular functions 
which are likely to be directly controlled by BCL6 during GC 
development, including activation, survival, DNA-damage 
response, cell cycle arrest, cytokine-, toll-like receptor-, 
TGFβ-, WNT-signaling and differentiation (2).
BCL6 protein is a 92- to 98-kDa nuclear phosphoprotein 
that is produced at low levels in several tissues and is expressed 
at high levels exclusively in GC B cells (3,4). High levels of 
BCL6 gene expression in non-Hodgkin's lymphomas have a 
favorable prognostic value (5,6). BCL6 contains an N-terminal 
BTB/POZ domain and 6 Kruppel-type (C2H2) zinc-finger 
(ZnF) motifs in the C terminus (7). The BTB/POZ domain 
displays a conserved protein-protein interaction motif that 
is required for the repressive activity of the protein (8). The 
BTB domain interacts with several other proteins which are 
members of the BTB/POZ-zinc finger family (BAZF, LRF, 
PLZF) (9-11). Although BCL6 contributes to lymphomagenesis 
by allowing conditions favorable to lymphoma pathogenesis, 
its precise role in the malignant transformation remains to be 
fully elucidated.
Logarajah et al (12) and Bos et al (13) reported that BCL6 
has an important function in breast cancer. Walters et al (14) 
evaluated the BCL6 protein expression in a subset of mesen-
chymal tumors. However, to our knowledge, there are no data 
on BCL6 expression/role in the adenoma-carcinoma sequence 
of colorectal carcinogenesis.
Colorectal cancer remains the second leading cause of 
cancer-related mortality in Western countries, and it develops 
mainly from adenomatous polyps and shows a morphological and 
genetic progression through an adenoma-carcinoma sequence, 
both in hereditary and in sporadic colorectal cancer (15). 
Microadenomas (MAs) have been generally accepted as precan-
cerous lesions on the basis of histopathological characteristics, 
biochemical and immunohistochemical features, as well as 
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genetic and epigenetic alterations (16-19). The purpose of the 
present study was two-fold: (i) to determine whether BCL6 
is expressed during malignant transformation of the large 
bowel and (ii) to assess whether, and to what extent, BCL6 
immunoreactivity is related to the different stages of neoplastic 
progression.
Therefore, samples of human normal mucosa, MA and 
cancer were evaluated with different methods, i.e., immunohis-
tochemistry, immunofluorescence and western blot analysis.
The results obtained showed a significant expression of 
BCL6 protein in preneoplastic and neoplastic lesions and 
suggest a possible involvement of BCL6 during the malignant 
transformation of colorectal mucosa.
Materials and methods
Study population. Twenty-two samples of normal colorectal 
mucosa (NM) were collected from 10 patients during colonos-
copy, at least 2 samples from each patient. One sample from 
each patient was fixed in formalin and embedded in paraffin 
for immunohistochemistry; the others were frozen at -80˚C. 
All patients had normal colonoscopy. Twenty-two MAs were 
also identified in 6 patients, and removed after operation for 
colorectal cancer on surgical specimens; the precise localiza-
tion of the lesion was made staining the resected mucosa with 
a 0.1% methylene-blue solution in saline, and observing it 
under a dissecting microscope in order to take and process 
only the fields of the lesion, as previously described (16,19). 
All MAs, defined as dysplastic aberrant crypt foci at histology 
were referred to as MAs. Ten MAs were fixed in formalin 
and embedded in paraffin, the others were frozen at -80˚C. 
Finally, 22 samples of colorectal cancer (K) were collected 
from 11 patients operated on for cancer, fixed in formalin or 
frozen at -80˚C. All cases of cancer were Dukes' C adenocar-
cinomas.
The patients enrolled in the present study, who underwent 
colonoscopy or surgical resection for colorectal cancer at the 
University Hospital of Modena, provided written informed 
consent to the study protocol, which was approved by the local 
Ethics Committee.
Immunohistochemistry. Ten samples of NM, 10 of MA, and 10 
of K were fixed in a 10% formalin solution for 1 h. They were 
then dehydrated, embedded in paraffin wax, and sectioned 
(3-µm thick); the sections were placed on Super Frost Plus 
microscope slides (Menzel). Prior to immunohistochemistry, 
routine histology of all tissue samples was carried out after 
hematoxylin and eosin (H&E) staining of the sections. Slides 
were dried overnight at 37˚C, dewaxed in 2 changes of fresh 
xylene, and rehydrated in a descending alcohol series. Antigen 
retrieval involved treatment with a protease (Pronase 1:20; 
DakoCytomation) for 7 min at 37˚C. Prior to immunohisto-
chemical staining, the sections were washed with PBS and 
blocked with 20% Swine Serum (Normal; DakoCytomation) 
in PBS for 30 min to reduce nonspecific antibody binding. 
Primary antibody was then applied at appropriate dilutions for 
30 min at room temperature. Polyclonal rabbit anti-mouse BCL6 
antibody (DakoCytomation) was used as primary antibody at a 
dilution of 1:200 in PBS. Endogenous peroxidase activity was 
blocked by treating the slides with 0.3% hydrogen peroxide 
in methanol for 12 min. After washing with PBS, biotinyl-
ated anti-mouse secondary antibody (1:20; DakoCytomation) 
was incubated for 30 min, and the slides were incubated with 
pre-diluted streptavidin-HRP conjugates for 30 min according 
to the manufacturer's instructions. In order to reveal the color 
of the antibody staining, DAB substrate solution (freshly made 
immediately prior to use: 0.05% DAB-0.015% H2O2 in PBS) 
was used. Slices were counterstained with Mayer's hema-
toxylin, dehydrated in ascending alcohol series and covered 
with a coverslip (Histovitrex mounting medium; Carlo Erba). 
For all these procedures, the negative control was obtained by 
staining samples without the primary antibody. Human B cell 
lymphomas were used as positive control.
Scoring system. One or 2 slices for each sample were scored 
as described below for immunofluorescence analysis. For each 
group of colorectal tissue and lesions, about 25 x100 micro-
scopic fields were scored. Moreover slices for each group of 
normal mucosa and lesions were scored by 2 independent 
observers and there was <5% variance between the results 
of the 2 counts. To quantify the staining area, the slices were 
processed with an ImageJ software. The images were converted 
into 16-bit images and then thresholded (the same value was 
used in all analyzed images). The resulting thresholded images 
were binary and they showed only the staining area. The total 
staining area was calculated by the software.
Immunofluorescence confocal microscopy. Immunofluo-
rescence analysis was carried out to evaluate the expression 
of BCL6 protein. Six samples of NM, 6 of MA and 6 of K, 
were fixed in 4% paraformaldehyde in PBS, cryoprotected 
in 15% sucrose in PBS, and frozen in isopentane cooled in 
liquid nitrogen. Horizontal cryosections of the samples were 
cut (10-µm thick), and H&E staining was performed on 
sections to control tissue integrity. After a treat ment with 3% 
BSA in PBS for 30 min at room temperature, the cryostatic 
sections were incubated with the primary antibodies (mouse 
anti-BCL6; DakoCytomation) diluted 1:25 in PBS containing 
3% BSA for 1 h at room temperature. After washing in PBS, 
the samples were incubated for 1 h at room temperature with 
the secondary antibodies diluted 1:20 in PBS containing 
3% BSA (sheep anti-mouse FITC-conjugated; Sigma). After 
washing in PBS and in H2O, the samples were counterstained 
with 1 µg/ml DAPI in H2O and then mounted with anti-fading 
medium (0.21 M DABCO and 90% glycerol in 0.02 M Tris, 
pH 8.0). Negative control samples were not incubated with 
the primary antibody. The confocal imaging was performed 
on a Leica TCS SP2 AOBS confocal laser scanning micro-
scope. For DAPI and FITC double detection, samples were 
sequentially excited with the 405-nm/25-mW lines of a blue 
diode laser and the 488-nm/20-mW lines of the Argon laser. 
The emission signals from DAPI and FITC were detected 
by 2 photomultiplier tubes. Excitation and detection of the 
samples were carried out in sequential mode to avoid overlap-
ping of signals. Sections were scanned with laser intensity, 
confocal aperture, gain and black-level setting kept constant 
for all samples. Optical sections were obtained at increments 
of 0.3-µm in the z-axis and digitized with a scanning mode 
format of 512x512 or 1,024x1,024 pixels and 256 grey levels. 
The confocal serial sections were processed with Leica LCS 
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software to obtain 3-dimensional projections. Image rendering 
was performed by adobe Photoshop software.
Evaluation of BCL6 immunofluorescence. The original green 
fluorescent confocal images were converted to grey-scale and 
median filtering was performed. An intensity value ranging 
from 0 (black) to 255 (white) was assigned to each pixel. 
Background fluorescence was subtracted and the immu-
nofluorescence intensity was calculated as the average for 
each selected area. To quantify BCL6 expression, all blocks 
were completely sectioned and 3-4 slices were examined at 
a magnification of x40 for each patient. Starting randomly, 
3 microscopic fields for each section were used for sampling 
all sections within the unbiased sampling frame. The fluo-
rescence intensity at the selected areas, linearly correlated 
with the number of pixels, was quantitatively analyzed using 
the standard imaging analysis software of the NIS-Elements 
system. To each sample was assigned a code number and 
Figure 1. Immunohistochemical staining of BCL6 in different human colonic tissues. (A and B) Normal mucosa at different magnifications. (C and D) MA at 
different magnifications. (E and F) Colorectal cancer at different magnifications. (G and H) High magnifications of MAs and colorectal cancer, respectively. 
The expression of BCL6 in samples of normal mucosa is low and restricted to the stromal compartment, as is well evident in both (A) transverse and in 
(B) longitudinal sections. The BCL6-positive cells show nuclear and cytoplasmic localization of the protein. MA samples are characterized by high expression 
at both the cytoplasmic and the nuclear level of fibroblast-like cells and leukocytes that fill the stromal compartment (dotted line). (C) Transverse section; 
(D) longitudinal section. In MA, the epithelial cells of the crypt show well evident BCL6 immunostaining, particularly in the (G) cytoplasm. In the lamina 
propria of colorectal cancer, the number of BCL6-positive fibroblast-like cells and leukocytes is significantly higher than in MA. (E and F) The protein is 
localized at both the cytoplasmic and the nuclear level. In colorectal cancer samples, diffuse high cytoplasmic and nuclear BCL6 expression is present in tumor 
cells (H). (A and D: bar, 50 µm; B: bar, 70 µm; C: bar, 100 µm; E: bar, 200 µm; F and H: bar, 50 µm; G: bar, 25 µm). MAs, microadenomas.
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the score, referred to as immunofluorescence intensity score, 
determined by an observer who was blind to tissue groups 
during analysis (20).
Western blot analysis. Whole cell lysates were obtained 
from 6 samples of NM, 6 of MA and 6 of K, extracted with 
hypotonic buffer (50 mM Tris-Cl, pH 7.8, containing 1% 
Figure 2. Confocal analysis of colonic mucosa cryosections labelled by DAPI (red) and anti-BCL6 (green). (A-C) Normal colorectal mucosa (C, merge): the 
BCL6 protein is localized mainly in stromal cells at the nuclear and cytoplasmic levels; the amount of immunostaining is low. (D-I) MA (F and I, merge): the 
marked increase of BCL6 staining with respect to normal mucosa is evident; (D-F) the protein is present in the nucleus as well as in the cytoplasm of stromal 
cells. (G-I) Crypt epithelial cells show marked staining mainly at the lateral borders of goblet cells. (J-O) Colorectal cancer. (J-L) In the stromal compart-
ment, the presence of many BCL6 labelled cells at the nuclear and cytoplasmic levels is evident. The immunostaining is significantly enhanced with respect 
to MAs. (M-O) BCL6 is also strongly expressed in the nucleus and in the cytoplasm of cancer cells. (A-C: bar, 50 µm; D-I: bar, 30 µm; J-O: bar, 25 µm). 
MAs, microadenomas.
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Nonidet P-40, 140 mM NaCl, 0.1% SDS, 0.1% Na deoxycholate, 
1 mM Na3VO4 and freshly added protease inhibitor cocktail). 
Lysates were then cleared by centrifugation for 15 min in a 
refrigerated centrifuge (1,500 rpm) and immediately boiled in 
SDS sample buffer. Protein extract (40 µg) from each sample 
(NM, MA and K) was electrophoresed on SDS-PAGE and 
transferred to nitrocellulose membranes. The protocols of the 
western blotting were performed as previously described (20). 
The membranes were blocked with 3% dry milk and 2% BSA 
in PBS-T and were then incu bated with mouse anti-BCL6 
(DakoCytomation) antibody, diluted 1:1,000 overnight at 4˚C 
under agitation. After washing, the membranes were incubated 
with secondary HPR-conjugated goat anti-mouse IgG antibody 
(1:10,000) for 30 min at room temperature. Immunoreactive 
proteins were detected with ECL (Amersham). Furthermore, 
the membranes were stripped and incubated with anti-mouse 
β-tubulin (Sigma) to control and correct for loading error. 
Densitometry analysis was performed using a Kodak Image 
Station 440CF system (Rochester, NY, USA).
Statistical analysis. All quantitative data for NM, MA and K 
are reported as means ± SD. The difference in BCL6 average 
expression in the different groups of colorectal lesions was 
tested for statistical significance using ANOVA one-way 
analysis, followed by Student-Newman-Keuls tests. P<0.05 
was considered to indicate a statistically significant difference 
between groups.
Results
Morphological evaluation. The quality of staining obtained 
by the immunohistochemical method was generally very 
good; BCL6 staining was evident as brown spots both in the 
cytoplasm and in the nucleus of stromal cells, easily allowing 
their identification even at low magnification. Examples of 
BCL6 staining are shown in Fig. 1, in which panels A and B 
show low levels of BCL6-positive cells (fibroblast-like cells 
and leukocytes) in NM, especially in the stroma adjacent to 
the crypts. In all samples of normal mucosa, appreciable BCL6 
staining of epithelial cells was not found. In MAs, BCL6 
expression was higher compared to normal mucosa and it 
was very evident in the stromal compartment (Fig. 1C and D). 
Moreover, a consistent epithelial positivity was observed in 
MA and K: the protein aggregated in small clumps appears 
distributed in the cytoplasm at the lateral and basal portions of 
the epithelial cells and also partially in their nucleus (Fig. 1G). 
Concerning the stromal compartment, the samples of K 
were characterized by a higher number of BCL6-positive 
cells with respect to MA (Fig. 1E and F); in carcinoma, 
positive cells were not evenly distributed in the tissue, but 
tended to gather in some areas, usually at the edge of the 
neoplastic tissue (Fig. 1E), not only in the stroma inside the 
tumor (Fig. 1F), but also among the neoplastic cells at the 
margins of the lesions (Fig. 1H). Inside the epithelial-positive 
cells, BCL6 protein accumulated predominantly at the apical 
region of cells towards the lumen of colonic crypts, as well as 
at the nuclear level (Fig. 1H). The semi-quantitative evaluation 
of immunostaining intensity reported as immunohistochem-
istry intensity score in Fig 3A, showed that the level of BCL6 
protein in both the epithelial and the stromal compartment 
had an increasing trend from NM to K, with statistical signifi-
cance of the different expression among the groups. In order 
to obtain a better resolution of subcellular structures in very 
thick samples, the confocal analysis of BCL6 was performed 
in a subset of NM, MA and K samples (Fig. 2). Moreover, this 
technique allowed to define the precise distribution pattern 
and the quantification of BCL6 protein. The staining patterns 
of BCL6 varied from a diffuse mode to a granular one, both 
in the cytoplasm and in the nucleus of stromal cells, appearing 
consistent and unchanged in the same samples, without 
appreciable variations in intensity and localization among the 
cells. In all NM samples, a few scattered areas in the stroma 
compartment exhibited a moderate BCL6-reactivity, although 
the epithelial cells were not marked (Fig. 2A-C). The results 
of immunofluorescence analysis were in line with those of 
immunohistochemistry: intense staining was evident in MA, 
in stromal cells surrounding colonic crypts (Fig. 2D-F); 
moreover, a moderate expression appeared in epithelial cells, 
Figure 3. (A) Immunohistochemistry intensity score of BCL6 in human normal colorectal mucosa (NM), microadenoma (MA) and colorectal cancer (K) in 
stromal and epithelial compartments. *#P<0.05 between all group pairs of samples. Bar, SD. (B) Immunofluorescence intensity score of BCL6 in NM, MA and 
K in stromal and epithelial compartments. *#P<0.05 between all group pairs of samples. Bar, SD. No positivity was recorded in the epithelial compartment of 
NM in either (A) or (B).
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but only at the cytoplasmic level (Fig. 2G-I). BCL6-positive 
cells were observed throughout the resected tissue in all colon 
cancer lesions and they were particularly numerous within 
the central tumor stroma (Fig. 2J-L). Some cells (both the 
epithelial and stromal ones) showed a strong BCL6 immunore-
activity in the cytoplasm as well as in the nucleus inside some 
tumor areas (Fig. 2M-O); in particular, they appeared located 
deeply, inside the tumor lesion. These features were confirmed 
by the measurement of the BCL6 expression levels, both in 
the epithelial and in the stromal compartment, by means of 
immunohistochemistry and immunofluorescence, that showed 
statistically significant differences in the 3 different types of 
samples (Fig. 3A and B). These results were in agreement with 
those obtained by immunohistochemical analysis.
Western blot quantification. To confirm the findings of the 
morphological evaluation previously described, cell lysates of 
NM, MA and K were analyzed by western blotting. The protein 
profile of BCL6 clearly showed 1 single weak band at the 
expected molecular weight (98-kDa) in NM, an intense band 
in MA and a very intense band in K (Fig. 4A). Densitometric 
analysis and normalization (with equal amounts of protein 
loading) of the immunoreactivity signal from protein extracts 
of NM, MA and K showed that the level of BCL6 protein has 
an increasing trend from NM to K, with statistical significance 
of the different expressions (Fig. 4B).
Discussion
The aim of the present study was to evaluate BCL6 expression 
during the neoplastic progression of human intestinal mucosa. 
BCL6 is a transcriptional repressor required in mature B cells 
during the germinal center (GC) reaction (3). The critical 
functions exerted by BCL6 during normal B-cell development 
can be hijacked by the malignant transformation process, thus 
indicating its critical involvement in colorectal cancer. Indeed, 
BCL6 is targeted by genetic aberrations and acts as an onco-
gene in GC-derived lymphomas (2); despite this, its precise 
role in the malignant transformation process remains to be 
fully elucidated. In non-hematolymphoid neoplasms, BCL6 
expression has been demonstrated in subsets of high grade 
ductal human carcinomas of the breast, both at the gene and 
the protein level (12,13).
To our knowledge, this is the first comprehensive report 
from morphological and quantitative analyses of BCL6 in 
human colorectal carcinogenesis, both in the epithelial and the 
stromal compartment. The results clearly outline that there is 
a marked increase in the intensity and density of staining for 
BCL6 protein in the normal mucosa-microadenoma-carcinoma 
sequence. Immunohistochemistry and immunofluorescence 
analyses showed that BCL6 is expressed in normal mucosa, 
although at low levels, whereas it significantly increases in 
microadenoma (MA) and in cancer with statistical significance. 
These results were confirmed by western blotting data, with no 
difference according to the various techniques used. In BCL6-
positive cells, both the nucleus and the cytoplasm appeared 
stained and this finding is in accordance with previous data on 
cellular localization of BCL6 in gastric cancer (21). Moreover, 
our observations consistently showing that the BCL6 protein 
is expressed only in the stromal compartment of the normal 
mucosa support some observations of other authors; BCL6 
was considered to be produced at low levels in various tissues, 
as reported in EST libraries obtained from several epithe-
lial tissues, although Hirata et al (21) reported that BCL6 is 
expressed in normal gastric epithelial cells and that it is not 
expressed in normal mucosa of colon and oesophagus. However, 
in their study, the authors did not examine the stromal compart-
ment of the colon and did not show quantitative data.
In addition, our data showed that the BCL6 protein is highly 
expressed in epithelial cells, in premalignant lesions as well 
as in carcinomatous tissues. For this reason, we hypothesized 
that the increased expression of the BCL6 protein is due to the 
transformation of the epithelium, that represents an important 
source of this protein.
Another notable consideration is that the BCL6 expression/
production by the epithelium appears to be linked to the early 
stages of carcinogenesis, since the positivity is strongly detect-
able in MAs. Although MAs are not the only microscopic 
lesions in the large bowel, they represent the most common 
precursors of cancer in this organ (22,23). In these neoplasms, 
the transformation process begins in the crypts and seems to 
result from qualitative, quantitative and spatial reorganization 
of some pathways that represent the physiologic regulator of 
epithelial homeostasis (24-26). Although the key role played 
by MAs in colorectal tumorigenesis is widely acknowledged, 
the modifications of gene expression that trigger or accompany 
their development have never been comprehensively studied. 
Figure 4. (A) Western blotting of BCL6 in human normal colorectal mucosa 
(NM), microadenoma (MA) and colorectal cancer (K). (B) Mean densito-
metric values of BCL6 protein expression level. *P<0.05 between all group 
pairs of samples. Bar, SD.
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This investigation identifies, for the first time, BCL6 as a puta-
tive marker of colorectal tumorigenesis and may also provide 
new insight for future molecular characterization of colorectal 
precancerous lesions.
Recently, Walters et al (14) examined a series of mesen-
chymal tumors with immunohistochemical and fluorescence 
in situ hybridization techniques. They reported that BCL6 
expression is relatively common in solitary fibrous tumor (SFT) 
and that, markedly, BCL6 protein seems to be significantly 
more expressed in malignant SFT, by the histological point of 
view, as compared to benign SFT. This finding is significant, 
inasmuch as our results suggest that the BCL6 protein may 
play some roles in the malignant transformation occurring 
in the large bowel. Our data should be validated with further 
investigations on premalignant and malignant lesions and/or 
different subtypes of colorectal cancer.
As is well known, microarray data serve as a springboard 
and reference point for further studies on the molecular 
basis of colorectal transformation along the adenocarcinoma 
pathway; in this regard, Saadi et al (27) recently carried out 
a gene set enrichment analysis (GSEA) to demonstrate that 
genes of the stromal cellular compartment discriminate pre-
invasive from invasive disease and suggest outcome prediction 
in digestive tumors, including colorectal cancer. The authors 
identified several genes, including BCL6, and underlined that 
the upregulation of this protein shows a trend for significantly 
poorer outcome in esophageal adenocarcinoma. Although the 
genes identified are relevant to Barrett's carcinogenesis, it is 
likely that these genes are involved in a dysregulated process 
common to other gastrointestinal tumors rather than being 
isolated critical oncogenes.
Furthermore, we consider immunohistochemistry critical 
in performing the identification of proteins which are current 
as well as new putative therapeutic targets. On the basis of our 
excellent results obtained by immunohistochemical analysis, 
fully confirmed by immunofluorescence and western blotting 
methods, it would be useful to determine whether the BCL6 
protein can be considered a histological marker for colorectal 
cancer.
Considering the well documented accuracy of the prog-
nostic relevance of BCL6 in large B-cell lymphomas (28-30), 
it is possible that quantification of BCL6 expression may have 
a potential role in risk evaluation of large bowel tumors.
In conclusion, the findings of the present study clearly 
show the qualitative and quantitative expression of BCL6 in 
human colorectal cancer development (in particular, the local-
ization of BCL6 expression in precancerous as well as tumor 
epithelia), and demonstrate that BCL6 appears to be involved 
in tumor progression, from the earliest stage of carcinogen-
esis. The improved understanding of the biological function 
of BCL6, the key role of which was already demonstrated 
in lymphomagenesis, should lead to a re-evaluation of the 
importance of this protein in other tissues and may highlight 
the relevance of performing further studies in order to identify 
novel therapeutic targets for colorectal cancer.
Acknowledgements
The present study was supported by funds of the ̔Fondazione 
di Vignola’ (Vignola-MO, Italy), the ̔Banca Popolare 
dell'Emilia Romagnaʼ (Modena, Italy) and the Cremonini 
Group (Castelvetro, MO, Italy). The authors thank the Centro 
Interdipartimentale Grandi Strumenti (C.I.G.S.) of the 
University of Modena and Reggio Emilia for software, instru-
ment availability and assistance, the Fondazione ALTEG 
(Associazione per la Lotta ai Tumori nell' Età Giovanile), the 
Fondazione Umberto Veronesi, and the Associazione per la 
Ricerca sui Tumori Intestinali (A.R.T.I), Modena, Italy.
References
  1. Dent AL, Shaffer AL, Yu X, Allman D and Staudt LM: Control 
of inflammation, cytokine expression, and germinal center 
formation by BCL-6. Science 276: 589-592, 1997.
  2. Basso K and Dalla-Favera R: Roles of BCL6 in normal and trans-
formed germinal center B cells. Immunol Rev 247: 172-183, 2012.
  3. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, 
Louie DC, Offit K, Chaganti RS and Dalla-Favera R: BCL-6 
protein is expressed in germinal-center B cells. Blood 86: 45-53, 
1995.
  4. Onizuka T, Moriyama M, Yamochi T, Kuroda T, Kazama A, 
Kanazawa N, Sato K, Kato T, Ota H and Mori S: BCL-6 gene 
product, a 92- to 98-kD nuclear phosphoprotein, is highly 
expressed in germinal center B cells and their neoplastic coun-
terparts. Blood 86: 28-37, 1995.
  5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, 
Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, 
Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, 
Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, 
Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO 
and Staudt LM: Distinct types of diffuse large B-cell lymphoma 
identified by gene expression profiling. Nature 403: 503-511, 2000.
  6. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, 
Zehnder JL, Tibshirani R and Levy R: Expression of a single 
gene, BCL-6, strongly predicts survival in patients with diffuse 
large B-cell lymphoma. Blood 98: 945-951, 2001.
  7. Dhordain P, Albagli O, Ansieau S, Koken MH, Deweindt C, 
Quief S, Lantoine D, Leutz A, Kerckaert JP and Leprince D: 
The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to 
nuclear dots and mediates homomerisation in vivo. Oncogene 11: 
2689-2697, 1995.
  8. Jardin F, Ruminy P, Bastard C and Tilly H: The BCL6 proto-
oncogene: a leading role during germinal center development 
and lymphomagenesis. Pathol Biol 55: 73-83, 2007.
  9. Okabe S, Fukuda T, Ishibashi K, Kojima S, Okada S, Hatano M, 
Ebara M, Saisho H and Tokuhisa T: BAZF, a novel Bcl6 
homolog, functions as a transcriptional repressor. Mol Cell 
Biol 18: 4235-4244, 1998.
10. Davies JM, Hawe N, Kabarowski J, Brand NJ, Leprince D, 
Dhordain P, Cook M, Morriss-Kay G and Zelent A: Novel 
BTB/POZ domain zinc-finger protein, LRF, is a potential target 
of the LAZ-3/BCL-6 oncogene. Oncogene 18: 365-375, 1999.
11. Dhordain P, Albagli O, Honore N, Guidez F, Lantoine D, 
Schmid M, The HD, Zelent A and Koken MH: Colocalization 
and heteromerization between the two human oncogene 
POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. Oncogene 19: 
6240-6250, 2000.
12. Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, 
Bobrow L, Venkitaraman A and Wagner S: BCL-6 is expressed 
in breast cancer and prevents mammary epithelial differentia-
tion. Oncogene 22: 5572-5578, 2003.
13. Bos R, van Diest PJ, van der Groep P, Greijer AE, Hermsen MA, 
Heijnen I, Meijer GA, Baak JP, Pinedo HM, van der Wall E and 
Shvarts A: Protein expression of B-cell lymphoma gene 6 (BCL-6) 
in invasive breast cancer is associated with cyclin D1 and hypoxia-
inducible factor-1α (HIF-1α). Oncogene 22: 8948-8951, 2003.
14. Walters MP, McPhail ED, Law ME and Folpe AL: BCL-6 
expression in mesenchymal tumours: an immunohistochemical 
and fluorescence in situ hybridisation study. J Clin Pathol 64: 
866-869, 2011.
15. Suehiro Y and Hinoda Y: Genetic and epigenetic changes in 
aberrant crypt foci and serrated polyps. Cancer Sci 99: 1071-1076, 
2008.
16. Di Gregorio C, Losi L, Fante R, Modica S, Ghidoni M, 
Pedroni M, Tamassia MG, Gafà L, Ponz de Leon M and 
Roncucci L: Histology of aberrant crypt foci in the human colon. 
Histopathology 30: 328-334, 1997.
SENA et al:  BCL6 IN HUMAN COLORECTAL CARCINOGENESIS8
17. Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L and 
De Pol A: Aberrant crypt foci in colorectal carcinogenesis. Cell 
and crypt dynamics. Cell Prolif 33: 1-18, 2000.
18. Takayama T, Miyanishi K, Hayashi T, Kukitsu T, Takanashi K, 
Ishiwatari H, Kogawa T, Abe T and Niitsu Y: Aberrant crypt 
foci: detection, gene abnormalities, and clinical usefulness. Clin 
Gastroenterol Hepatol 3 (Suppl 1): S42-S45, 2005.
19. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, 
Pedroni M, Luppi D, Santoro L, Monni S, Manenti A, Bertani A, 
Merighi A, Benatti P, Di Gregorio C and de Leon PM: 
Myeloperoxidase-positive cell infiltration in colorectal carcino-
genesis as indicator of colorectal cancer risk. Cancer Epidemiol 
Biomarkers Prev 17: 2291-2297, 2008.
20. Sena P, Roncucci L, Marzona L, Mariani F, Maffei S, Manenti A 
and De Pol A: Altered expression of apoptosis biomarkers in 
human colorectal microadenomas. Cancer Epidemiol Biomarkers 
Prev 19: 351-357, 2010.
21. Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, 
Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, Kataoka H, 
Kamiya T, Higashiyama S and Joh T: BCL6 degradation caused 
by the interaction with the C-terminus of pro-HB-EGF induces 
cyclin D2 expression in gastric cancers. Br J Cancer 100: 1320-1329, 
2009.
22. Roncucci L, Medline A and Bruce WR: Classification of 
aberrant crypt foci and microadenomas in human colon. Cancer 
Epidemiol Biomarkers Prev 1: 57-60, 1991.
23. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, 
Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y: Aberrant 
crypt foci of the colon as precursors of adenoma and cancer. 
N Engl J Med 339: 1277-1284, 1998.
24. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, 
Kinzler KW, Vogelstein B and Clevers H: Constitutive tran-
scriptional activation by a β-catenin-Tcf complex in APC-/-colon 
carcinoma. Science 275: 1784-1787, 1997.
25. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, 
Vogelstein B and Kinzler KW: Activation of β-catenin-Tcf 
signalling in colon cancer by mutations in β-catenin or APC. 
Science 275: 1787-1790, 1997.
26. Pinto D and Clevers H: Wnt, stem cells and cancer in the intestine. 
Biol Cell 97: 185-196, 2005.
27. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, 
Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, 
Balkwill F and Fitzgerald RC: Stromal genes discriminate prein-
vasive from invasive disease, predict outcome, and highlight 
inflammatory pathways in digestive cancers. Proc Natl Acad Sci 
USA 107: 2177-2182, 2010.
28. Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D 
and Torlakovic E: Expression of bcl-6 and CD10 protein is asso-
ciated with longer overall survival and time to treatment failure 
in follicular lymphoma. Am J Clin Pathol 121: 34-42, 2004.
29. Berglund M, Thunberg U, Amini RM, Book M, Roos G, 
Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, 
Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, 
Rosenquist R and Enblad G: Evaluation of immunophenotype in 
diffuse large B-cell lymphoma and its impact on prognosis. Mod 
Pathol 18: 1113-1120, 2005.
30. Levy O, Deangelis LM, Filippa DA, Panageas KS and Abrey LE: 
Bcl-6 predicts improved prognosis in primary central nervous 
system lymphoma. Cancer 112: 151-156, 2008.
